Syndax Pharmaceuticals Inc financial data

Symbol
SNDX on Nasdaq
Industry
Pharmaceutical Preparations
Location
730 Third Avenue, 9 Th Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 749 % -37.6%
Debt-to-equity 37.3 % +323%
Return On Equity -80.7 % -68.5%
Return On Assets -58.7 % -33.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 86M shares +1.22%
Common Stock, Shares, Outstanding 85.7M shares +1.02%
Entity Public Float 1.7B USD
Common Stock, Value, Issued 9K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 85.6M shares +21.7%
Weighted Average Number of Shares Outstanding, Diluted 85.6M shares +21.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 12.5M USD
Research and Development Expense 242M USD +48.2%
General and Administrative Expense 31.1M USD +80.1%
Operating Income (Loss) -340M USD -47.7%
Nonoperating Income (Expense) 20.9M USD +1.55%
Net Income (Loss) Attributable to Parent -319M USD -52.3%
Earnings Per Share, Basic -3.72 USD/shares -24.8%
Earnings Per Share, Diluted -3.72 USD/shares -24.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 154M USD -47.8%
Accounts Receivable, after Allowance for Credit Loss, Current 7.6M USD
Inventory, Net 366K USD
Other Assets, Current 3.51M USD
Assets, Current 603M USD +3.82%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 2.02M USD +36%
Other Assets, Noncurrent 0 USD -100%
Assets 725M USD +18.3%
Accounts Payable, Current 11.6M USD +16.7%
Employee-related Liabilities, Current 14.5M USD +29.6%
Liabilities, Current 104M USD +78.2%
Operating Lease, Liability, Noncurrent 1.58M USD +173%
Liabilities 437M USD +644%
Retained Earnings (Accumulated Deficit) -1.22B USD -35.3%
Stockholders' Equity Attributable to Parent 288M USD -48%
Liabilities and Equity 725M USD +18.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -83.5M USD -113%
Net Cash Provided by (Used in) Financing Activities 2.17M USD -12.4%
Net Cash Provided by (Used in) Investing Activities -99.4M USD -599%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 85.6M shares +22.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -181M USD -974%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 259M USD +25.6%
Deferred Tax Assets, Gross 259M USD +25.6%
Operating Lease, Liability 2.05M USD +27%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -319M USD -53%
Lessee, Operating Lease, Liability, to be Paid 2.45M USD +35.8%
Property, Plant and Equipment, Gross 419K USD 0%
Operating Lease, Liability, Current 471K USD -54.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 656K USD +8.25%
Lessee, Operating Lease, Liability, to be Paid, Year One 657K USD -45.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 399K USD +111%
Lessee, Operating Lease, Liability, to be Paid, Year Three 675K USD
Deferred Tax Assets, Operating Loss Carryforwards 43.4M USD +32.8%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 143K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 43M USD +39%
Interest Expense 233K USD -87.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%